share_log

Sera Prognostics | 8-K: SERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS

Sera Prognostics | 8-K: Current report

Sera Prognostics | 8-K:重大事件
SEC announcement ·  03/21 04:16
牛牛AI助理已提取核心訊息
On March 20, 2024, Sera Prognostics, a health diagnostics company specializing in pregnancy care, announced its financial results for Q4 and the fiscal year ending December 31, 2023. The company reported Q4 revenue of $41,000, a decrease from $65,000 in the same period of 2022. Total operating expenses for Q4 decreased to $8.9 million from $10.5 million in the previous year. The net loss for Q4 was $7.9 million, an improvement from a $9.7 million loss in Q4 2022. For the full year, revenue increased to $306,000 from $268,000 in 2022, with total operating expenses reducing to $40.1 million from $45.9 million. The annual net loss narrowed to $36.2 million from $44.2 million. The company highlighted progress in its PRIME study for preterm birth risk assessment, product pipeline development, and commercial strategy focusing on expectant mothers. As of December 31, 2023, Sera Prognostics had approximately $79.9 million in cash, cash equivalents, and securities. The company also hosted a conference call and webcast to discuss these results and operational highlights.
On March 20, 2024, Sera Prognostics, a health diagnostics company specializing in pregnancy care, announced its financial results for Q4 and the fiscal year ending December 31, 2023. The company reported Q4 revenue of $41,000, a decrease from $65,000 in the same period of 2022. Total operating expenses for Q4 decreased to $8.9 million from $10.5 million in the previous year. The net loss for Q4 was $7.9 million, an improvement from a $9.7 million loss in Q4 2022. For the full year, revenue increased to $306,000 from $268,000 in 2022, with total operating expenses reducing to $40.1 million from $45.9 million. The annual net loss narrowed to $36.2 million from $44.2 million. The company highlighted progress in its PRIME study for preterm birth risk assessment, product pipeline development, and commercial strategy focusing on expectant mothers. As of December 31, 2023, Sera Prognostics had approximately $79.9 million in cash, cash equivalents, and securities. The company also hosted a conference call and webcast to discuss these results and operational highlights.
2024年3月20日,專門從事孕期護理的健康診斷公司Sera Prognostics公佈了第四季度和截至2023年12月31日的財年的財務業績。該公司公佈的第四季度收入爲41,000美元,低於2022年同期的65,000美元。第四季度的總運營支出從去年的1,050萬美元降至890萬美元。第四季度的淨虧損爲790萬美元,較2022年第四季度的970萬美元虧損有所改善。全年收入從2022年的26.8萬美元增加到30.6萬美元,總運營支出從4590萬美元減少到4,010萬美元。年度淨虧損從4,420萬美元縮小至3620萬美元。該公司重點介紹了其早產風險評估、產品管道開發和以準媽媽爲重點的商業戰略的PRIME研究的進展。截至2023年12月31日,Sera Prognostics擁有約7,990萬美元的現金、現金等價物和證券。該公司還舉辦了電話會議和網絡直播,討論了這些業績和運營亮點。
2024年3月20日,專門從事孕期護理的健康診斷公司Sera Prognostics公佈了第四季度和截至2023年12月31日的財年的財務業績。該公司公佈的第四季度收入爲41,000美元,低於2022年同期的65,000美元。第四季度的總運營支出從去年的1,050萬美元降至890萬美元。第四季度的淨虧損爲790萬美元,較2022年第四季度的970萬美元虧損有所改善。全年收入從2022年的26.8萬美元增加到30.6萬美元,總運營支出從4590萬美元減少到4,010萬美元。年度淨虧損從4,420萬美元縮小至3620萬美元。該公司重點介紹了其早產風險評估、產品管道開發和以準媽媽爲重點的商業戰略的PRIME研究的進展。截至2023年12月31日,Sera Prognostics擁有約7,990萬美元的現金、現金等價物和證券。該公司還舉辦了電話會議和網絡直播,討論了這些業績和運營亮點。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。